# Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCC

> **NCT04791176** · PHASE2 · COMPLETED · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 64 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Radiotherapy
- Lenvatinib

## Interventions

- **RADIATION:** concurrent lenvatinib and Radiotherapy, followed lenvatinib maintenance

## Key facts

- **NCT ID:** NCT04791176
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-12
- **Primary completion:** 2024-06-30
- **Final completion:** 2025-05-23
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2025-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04791176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04791176, "Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04791176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*